At this year’s International Alzheimer’s Conference, the results of the Phase 3 clinical drug trial for LMTM, a drug targeting the build up of Tau protein, were announced. These results have been eagerly awaited, as LMTM is the first drug targeting Tau protein to reach advanced clinical testing. Alzheimer’s is Read More…
Archive for August, 2016
A Disappointing Alzheimer’s Association International Conference
The 2016 Alzheimer’s Association International Conference has just ended, with few encouraging developments. Here are the highlights:
A decline in one’s sense of smell may herald the onset of Alzheimer’s
A thinning of the retina may be an early indicator of Alzheimer’s
A change in personality or behavior may accompany the onset of Read More…
